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Abstract 
 
INTRODUCTION: Prospective studies reporting associations between cognitive performance and subsequent incident 
dementia, have been subject to attrition bias. Furthermore, the extent to which established risk factors account for such 
associations requires further elucidation.  
 
METHODS: We used UK Biobank baseline cognitive data (n≤488 130) and electronically-linked hospital inpatient and 
death records during three to eight-year follow-up, to estimate risk of total dementia (n=1051), Alzheimer’s disease 
(n=352), and vascular dementia (n=169) according to four brief cognitive tasks, with/without adjustment for 
constitutional and modifiable risk factors. 
 
RESULTS: We found associations of cognitive task performance with all-cause and cause-specific dementia (p<0.01); 
these were not accounted for by established risk factors. Cognitive data added up to 5% to the discriminative accuracy 
of ROC curve models; areas under the curve ranged from 82% to 86%. 
 
DISCUSSION: This study offers robust evidence that brief cognitive testing could be a valuable addition to dementia-
prediction models.  
 
Keywords: Alzheimer’s disease; APOE e4; Dementia; Modifiable risk factors; Polygenic risk; cognitive performance; 
ROC; Vascular dementia. 
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1. Introduction 
 
Cognitive performance on psychometric tests among older adults without dementia are predictive of incident all-cause 
dementia and/or Alzheimer’s disease (AD) according to prospective cohort studies (1,2). Performance scores for global 
cognitive function (i.e. a composite of tests from multiple cognitive domains) discriminate between incident 
dementia/AD cases and non-dementia (3–6). Tests of specific cognitive domains that are most predictive include 
episodic memory (5,7–9), executive function (10,11), verbal fluency (7,8,11), and processing speed (11,12). Such 
cognitive data could therefore be usefully incorporated into dementia risk prediction models for population health 
monitoring, alongside more established constitutional and modifiable risk factors. A recent systematic review identified 
17 population-based prospective studies reporting on the discriminative accuracy of cognitive tests for predicting 
incident dementia (1), all of which reported moderate values (areas under the curve (AUC) from models adjusting for 
age, sex and education ranged from 0.70 to 0.89), for follow-up periods spanning one to ten years. In all studies, dementia 
case ascertainment was by in-person clinical assessment of study participants, and therefore model estimates are subject 
to self-selection bias; for example, retained cohort members have on average better cognitive function than those who 
drop out. This issue, compounded in older-aged cohorts, can also lead to studies being severely underpowered as well 
as biased. Whereas case ascertainment from routinely collected electronic data is sometimes adopted in dementia 
epidemiological studies (13,14), it has not so far been used to address this research topic, with the exception of studies 
linking childhood cognitive ability to later life dementia risk (15–17). In the present study we consider the discriminative 
accuracy of cognitive test performance in predicting incident dementia, ascertained by linkage to electronic hospital and 
mortality records, in the largest study to date: the UK Biobank prospective study of 502,617 adults.   
The baseline data from UK Biobank enable the study of a range of genetic and environmental exposures, to help 
better understand preclinical and prodromal stages of diseases (18)—particularly with its ongoing linkage to primary 
(i.e. general practice databases) and secondary health databases (i.e. hospital admissions and death records) (19). 
Investigating health trajectories in the decades leading up to dementia onset is important for understanding its complex 
aetiology, and validating its associated risk factors, given the early neuropathological changes that can occur decades 
prior to diagnosis (20). However, whereas cognitive testing with psychometric assessment promises to be a non-
invasive, convenient means of indicating associated changes to cognitive function, the baseline cognitive tests 
administered to UK Biobank participants were particularly brief (21). We therefore assess whether performance on these 
tests can aid in the prediction of incident dementia during relatively short-term follow-up of this cohort. If they can, then 
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these tests may be sufficiently sensitive for observing cognitive change over the longer term, particularly in conjunction 
with an enhanced cognitive test battery at participant follow-up 
(http://biobank.ctsu.ox.ac.uk/crystal/label.cgi?id=100026).  
 The further intention of this paper is: (i) to assess whether any associations between baseline cognitive 
performance and incident dementia may be accounted for by constitutional and/or modifiable risk factors for dementia, 
which could inform an understanding of mechanistic pathways; and (ii) whether cognitive scores add anything to 
prediction models of the disease. We are aware of only one other population cohort study to date ─ the German Study 
of Aging Cognition and Dementia ─ that has considered preclinical cognitive performance in conjunction with both 
genetic and modifiable risk factors of dementia (6). The present study considers a range of constitutional and genetic 
factors (i.e. family history of dementia, APOE e4 genotype, and, polygenic risk scores for AD), as well as well-validated 
modifiable risk factors (22), including major depressive disorder, hypertension, low physical activity, diabetes, obesity, 
high cholesterol, and smoking.  
 
2. Methods 
 
2.1 Study population 
UK Biobank recruited 502 617 people aged between 40-69 years from across the UK between 2006 and 2010, to 
take part in a longitudinal study of health and well-being (18). During baseline assessment participants completed 
touchscreen cognitive tests and self-report questionnaires, and nurse interviews for physical measures and validation of 
self-report health-related measures. They provided blood samples for genetic analysis and were asked for consent to 
follow-up through linkage of their health data to their study data. Genome-wide genotyping data were analysed from 
blood samples of 488,363 participants. Incident health outcomes can be identified through linkage to hospital admissions 
and mortality datasets.  
 
2.2 Assessment of cognitive function 
Cognitive function was assessed using four computer-administered tests (see Table 1 for details). The bespoke 
cognitive test battery was intentionally brief and designed to tap into cognitive domains that are sensitive to ageing 
and/or pathological processes (i.e. fluid cognitive abilities), including processing speed (reaction time task), visual 
episodic memory (visual pairs memory task), and prospective memory (prospective memory task). In addition, a verbal-
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numerical reasoning task that assesses both fluid and crystallised abilities, showed the highest loading on a general 
cognitive ability factor according to a psychometric analysis of this battery (21). The prospective memory and verbal-
numerical reasoning tasks were introduced during the last two years of UK Biobank recruitment, and therefore data on 
these are available for approximately one third of the cohort.  
 
[Table 1 about here] 
 
2.3 Ascertainment of incident dementia 
Dementia syndromes, including all-cause, AD and vascular dementia (VaD), were identified from ICD9 and 
ICD10 (international classification of diseases, 9th and 10th revisions) codes of hospital inpatient admissions data from 
1996 to February 2016 (provided by Hospital Episode Statistics in England; for corresponding start dates and annual 
censoring dates from Scottish Morbidity Records  and Patient Episode Database for Wales see: 
https://biobank.ctsu.ox.ac.uk/crystal/exinfo.cgi?src=Data_providers_and_dates), and from ICD10 codes on death 
certificates issued between April 2006 and February 2016 (see Table S1 for ICD codes), downloaded from UK 
Biobank’s data showcase on 29th November 2017 (http://biobank.ndph.ox.ac.uk/showcase/). Data linkage processes 
including permissions were managed by UK Biobank, and participant identifiers (NHS number, date of birth, sex, and 
postcode) were submitted to external organisations for secure matching to their respective secondary healthcare records 
(for more details see: https://biobank.ctsu.ox.ac.uk/crystal/docs/DataLinkageProcess.pdf), which included primary and 
secondary diagnoses within hospital admissions, and underlying and secondary causes of death from morbidity records. 
We selected incident dementia cases if the date of first recorded diagnosis for an individual occurred at least three years 
after the date of their baseline assessment, excluding participants with diagnoses earlier than this to reduce the likelihood 
of including prevalent cases in our analyses. We also excluded those who self-reported having ‘dementia, Alzheimer’s 
disease, or cognitive impairment’ at the baseline nurse interview (n=56 not detected by hospital admissions records).  
 
2.4 Constitutional and modifiable risk factors  
Table 2 includes details of the dementia risk factors included as covariates in the present study. Constitutional 
risk factors for dementia include: age, sex, education, family history of dementia, APOE e4 carrier status, AD polygenic 
score, and, neuroticism. We selected seven modifiable risk factors for dementia validated in a recent systemic review 
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and expert panel study (23), including depression (current risk and past history), hypertension, hyperlipidaemia, 
diabetes, obesity (and central obesity), smoking, and, low physical activity.   
 
[Table 2 about here] 
 
2.5 Statistical analysis 
Age and sex-adjusted logistic regression models were used to represent the fundamental associations between 
each independent variable (cognitive, constitutional, and modifiable risk factors) and dementia risk (total, AD and VaD). 
The independent variables of significance in univariate analysis were then included in multiple logistic regression 
models (complete cases only): Model 1 included age, sex, education, and one of the four cognitive test variables; Model 
2 added constitutional risk factors (i.e. APOE e4, family history of dementia and neuroticism) to Model 1; Model 3 
added modifiable risk factors to those variables entered into Model 2, including current and past depression, 
hypertension, hypercholesterolemia, diabetes, and smoking. To address bias due to data not missing completely at 
random, these multiple logistic regression models were repeated to include participants with missing data on covariates 
with >5% missingness in the total sample, and results were compared with those from models including complete cases 
only (see Supplementary Methods B for details of missingness). Thirdly, we considered the discriminative accuracy for 
predicting incident dementia risk according to those variables that were shown to independently predict the outcomes, 
by plotting receiver operating characteristic (ROC) curves and deriving AUC.    
 
 
3. Results 
3.1 Descriptive characteristics of the sample 
We identified 1051 cases of incident dementia (including 352 AD; 169 VaD) via electronic linkage to hospital 
admission and death certificate data during the period three to eight years after cognitive testing (5.2 median years of 
follow-up; 2.1 cases per 1000 population – slightly lower than rates reported in similarly aged UK cohorts (23,24)). Of 
the original UK Biobank cohort, 385 336 participants including 591 dementia cases had complete data on reaction time, 
visual memory, and covariates, and were therefore included in the first set of univariate analyses (‘main analytic 
sample’). Models including genetic data were based upon a subset of this sample: 65 824 participants and 112 dementia 
cases (‘genetic sample’). A second subset were used in analyses of the remaining two cognitive tests (‘full cognitive 
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battery sample’), involving 130 212 participants and 115 dementia cases who had complete data on verbal-numerical 
reasoning and prospective memory. The mean lag times between cognitive testing and dementia diagnosis were similar 
for the total sample (n = 1051; M = 5.23 years) and the main analytic sample (n = 591; M = 5.24 years) (see Figure S1 
for distribution of lag times). Those who were excluded from analyses due to missing data were on average older at 
dementia diagnosis (69.4 years vs. 66.2 years), and, showed a higher dementia incidence (0.39% vs. 0.15%); they also 
showed slightly greater modifiable risk factors for dementia than the analytic sample, they were less likely to have 
graduated from college, and they were poorer scorers on average on the cognitive tests (see S5 Table). There were no 
differences between the analytic and excluded samples on genetic status, including APOE e4.  
 
3.2 Association of individual risk factors for dementia 
In age- and sex-adjusted models each constitutional risk factor─with the exception of AD polygenic score─was 
significantly associated with total incident dementia (see Table 3 for full results): positive APOE e4 carrier status (OR 
= 2.99; 95%CI: 2.43 to 3.68), having a family history of dementia (1.65 [1.36 to 2.00]), no college degree (1.48 [1.22 
to 1.81]), high neuroticism (1.45 [1.15 to 1.84]), male sex (1.39 [1.18 to 1.63]), , and older age (1.21 [1.19 to 1.23] per 
year). 
Similarly, the majority of modifiable risk factors were significantly associated with dementia risk: baseline 
depression rating (OR = 2.25; 95%CI: 1.67 to 3.03), diabetes (1.75 [1.36 to 2.26]), current smoking (1.53 [1.17 to 2.01]), 
history of depression (1.47 [1.24 to 1.74]), hypertension (1.39 [1.17 to 1.64]), and high cholesterol (1.36 [1.14 to 1.61]). 
Total obesity risk (i.e. BMI ≥30) and central obesity were not significantly associated with all-cause dementia risk in 
this population (1.12 [0.97 to 1.28]; 1.16 [0.97, 1.40]); neither was low physical activity (1.23 [0.98 to 1.54]). In 
sensitivity analysis the odds ratios for total dementia risk according to these modifiable risk factors were somewhat 
weaker compared to analyses that included incomplete cases (data available in S6 Table). In further sensitivity analyses 
univariate models were repeated with death included as an outcome, and survival bias was viewed as unlikely for most 
factors (see Table S7).  
The above risk factors were differentially related to risk of AD and VaD. For example, APOE e4 genotype was 
more strongly predictive of incident AD than incident VaD (4.28 [2.97 to 6.18] vs. 2.22 [1.33 to 3.70]), whereas being 
male was more predictive of VaD versus AD (1.81 [1.19 to 2.75] vs. 1.04 [0.78 to 1.38]. In addition, of the modifiable 
risk factors we investigated current depression, hypertension, high cholesterol, and diabetes, were each significantly 
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predictive of VaD, whereas only current depression was predictive of incident AD (see Table 3 for individual effect 
sizes).    
 
[Table 3 about here] 
 
3.3 Prediction of incident dementia by baseline cognitive performance 
3.3.1 Univariate analyses 
Baseline performances on all four cognitive tests were significantly predictive of incident dementia during three 
to eight years of follow-up, after adjustment for age, sex and education (see Table 4). A one standard deviation (SD) 
higher verbal-numerical reasoning error score was associated with 68% higher odds of dementia diagnosis (OR = 1.68; 
95%CI: 1.36 to 2.07); a one SD higher mean reaction time (i.e., a slower reaction time, indicating poorer performance) 
was associated with 31% higher odds (1.31 [1.22 to 1.41]); and a one SD higher number of errors on the visual memory 
task was associated with 27% higher odds of dementia (1.27 [1.18 to 1.36]). Whereas the magnitude of these effect sizes 
are relatively low (if we compare them to those of established risk factors, i.e. APOE e4, current depression), an incorrect 
first response on the prospective memory task was associated with over three times the odds of dementia (3.28 [2.26 to 
4.75]). The effect sizes for total dementia risk according to reaction time and visual memory respectively were similar 
for the main analytic sample versus the sample with incomplete cases (see Table S8 for sensitivity analyses). 
Furthermore, there were no obvious differences between the odds ratios for dementia diagnoses made within three to 
five years of cognitive testing, and those for dementia diagnoses made six to eight years later (see Table S8). 
For the dementia subtype prediction models, reaction time was more highly predictive of VaD (1.56 [1.32 to 
1.84]) than AD (1.24 [1.09 to 1.41]) (comparison of natural logs of OR: Z=2.15; p=0.031), whereas visual memory 
performance was associated to a similar extent with AD and VaD respectively (1.24 [1.10 to 1.41]) vs 1.20 [1.00 to 
1.44]) (see Table 4).2.86 [1.20 to 6.80])  Although models for the other two cognitive tasks showed higher point 
estimates for AD than VaD, confidence intervals were wide and overlapping, and case numbers low.  
 
[Table 4 about here] 
 
 
3.3.2 Adjustment for constitutional and modifiable risk factors 
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Despite the differential association of risk factors with incident AD and VaD respectively, we first conducted 
an adjusted analyses by these risk factors on the association between cognitive performance and all-cause dementia. 
This was warranted given the higher proportion of ‘unspecified dementia’ diagnoses in this sample compared to either 
subtype (Table S1), the likelihood of additional AD and VaD cases among this unspecified group, and, the subsequent 
loss of statistical power if we were to restrict analyses to AD and VaD endpoints only. In multiple logistic regression 
models sample sizes increased after excluding covariates that were non-significant in univariate analyses. Table 5 reports 
the results of these models where the associations between cognitive domain-related tests and all-cause dementia risk, 
were adjusted for constitutional risk factors (with and without APOE e4), then additionally for modifiable risk factors. 
These did little to account for any of the associations between cognitive task performance and dementia risk in the 
present study, which remained statistically significant in fully-adjusted models. For example, the ORs for dementia in 
basic and fully-adjusted models were: 1.31 (95%CI: 1.20, 1.43) and 1.31 (1.20, 1.43) according to a one SD slower 
reaction time; 1.21 (1.11, 1.32) and 1.19 (1.09, 1.30) for one SDs higher in visual memory errors; 1.87 (1.42, 2.48) and 
1.72 (1.06, 2.81) for one SDs higher in verbal-numerical reasoning errors; 3.50 (2.15, 5.67) and 3.00 (1.30, 6.96) for an 
incorrect first response in prospective memory. Other independent variables that retained significance in multiple 
regression included age, sex, APOE e4, family history of AD, and self-rated depression (see Tables S9-S12 for effect 
estimates). Sensitivity analyses found no evidence that excluding cases due to substantive missing data on exposures 
would have biased these results (see Table S13).  
Multiple logistic regression models were run to predict dementia subtypes in association with reaction time and 
visual memory respectively. In a basic model the OR for incident AD was 1.29 (95%CI: 1.12, 1.49) according to a one 
SD slower reaction time, compared to 1.30 (1.13, 1.50) in a fully-adjusted model (see Table S9). The ORs for VaD 
according to a one SD slower reaction time in the basic and fully-adjusted models were 1.58 (1.36, 1.84) and 1.53 (1.32, 
1.78) respectively. Similarly, the inclusion of constitutional and modifiable risk factors did very little to account for the 
associations between visual memory, and AD and VaD respectively (Table S10 reports these results).  
 
[Table 5 about here] 
 
3.4 Discriminative accuracy of models, with and without cognitive variables 
 Figure 1 displays ROC curves for all-cause dementia prediction models, with age, sex and education entered in 
the first model, followed by the addition of family history with or without APOE e4 (model 2), + self-rated depression 
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(model 3), and + cognitive performance on all four tests (model 4). Whereas genetic testing is becoming more cost-
effective, the decision to determine the predictive accuracy of a model without APOE e4 was because participants of 
research studies don’t always consent to use of their genetic data. Therefore, the analyses included: 81 823 (78 dementia 
cases) with no missing data when APOE e4 status was included (Figure 1, left graph), and, 145 068 participants (141 
dementia cases) when APOE e4 was excluded (Figure 1, right graph). The AUC values for model 4 were moderately 
good (83% to 86% respectively), and each of the cognitive tests contributed to the models (see Table S14). The addition 
of reaction time, visual memory, verbal-numerical reasoning, and prospective memory to ROC curves that included age, 
sex, education, family history of AD, and depression, with or without APOE e4 status, significantly improved the 
models’ predictive power according to chi-square tests, contributing an additional 5% to the discriminative accuracy of 
the ROC curves. 
For comparison with previous studies we reproduced ROC curves adding the four cognitive test variables to a 
basic model that included age, sex and education only (n=160 903; cases=177). The AUC value went from 0.763 
(95%CI: 0.729, 0.796) to 0.821 (0.790, 0.853), χ2 = 31.9, p <.001.  
 
[Figure 1 about here] 
 
Discussion 
 
Our study has demonstrated an association between preclinical cognitive capability in adulthood and risk of incident 
dementia ascertained through data linkage to routine electronic health records, thereby avoiding the issue of attrition 
common to previous studies. In a dementia-free sample at baseline we observed associations between performance on 
very brief tests of reaction time, visual memory, prospective memory, and verbal-numerical reasoning and incident all-
cause dementia during three to eight-year prospective follow-up. The cognitive scores were also each related to specific 
dementia subtypes AD and VaD. Despite including established risk factors for dementia in the models, the findings 
regarding preclinical cognitive performance were independent of genetic and other constitutional factors, as well as 
seven modifiable risk factors. The cognitive tests together added up to 5% to the discriminative accuracy of ROC curves 
that included age, sex, family history of dementia, APOE e4, and, depression (AUC was 0.86 in the fully-adjusted 
model). 
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A limitation of the present study is the potential under-detection of incident dementia cases due to referral bias. 
This may have been a factor in the hospital admissions data due to individual differences in health care-seeking 
behaviour. However, such bias may be less than expected among UK Biobank participants who are more likely to seek 
health care given their willingness to voluntarily participate in health research. In 2012, hospitals in England saw the 
introduction of routine dementia assessment for old-aged patients, which may further reduce this bias. Since then 
improvements in sensitivity and specificity of dementia diagnoses in hospitals in England have been reported (25), 
although the validity of recording VaD in hospital inpatient records, in particular, could still be improved (26,27). 
Identification of dementia cases through electronic health linkage without use of primary care data (unavailable to us), 
may also have led to under-detection of dementia, which has been observed in a Scottish subsample of UK Biobank 
(27). Evidence from the Million Women Study has demonstrated the reliability of using secondary health care records 
for dementia ascertainment, and their agreement with primary care diagnoses (28), yet, dementia codes appeared in 
primary care data on average 1.6 years before hospital admission data, for people who receive both. Referral bias in the 
present analysis is therefore likely to be inversely related to duration of follow-up. We optimised use of the secondary 
health care data available to us by selecting ICD codes of specific dementia subtypes as well as general dementia, and, 
by combining data from hospital and mortality records, which have been shown to improve positive predictive validity 
and sensitivity respectively of detecting dementia (14). It is uncertain how a degree of under-detection could have 
influenced our results, although we speculate that this may have produced more conservative odds ratios for dementia 
risk, at least according to the modifiable and cognitive exposures. A further limitation of the study was the low to 
moderate test-retest reliability of the cognitive tests (21). The UK Biobank baseline cognitive assessment was designed 
to be very brief due to the wide array of data types that were collected on participants, and therefore the tests were 
necessarily bespoke. If time had allowed for a more extensive test battery, we may have observed higher discriminative 
accuracy from cognitive assessment. Thirdly, missing data from participants with lower cognitive ability and/or poorer 
health, were likely to have reduced the sensitivity of the analysis due to selective attrition, albeit in repeat analyses the 
inclusion of participants with missing data saw little change to the effect sizes. Finally, the prediction modelling of the 
present study does not allow us to comment on causal or explanatory mechanisms for the observed associations between 
risk factors and incident dementia. By including education in the models, we will have controlled, to some extent, for 
pre-morbid cognitive ability. Yet the lower cognitive performance ─ as well as higher rates of depression (23) ─ of 
participants with dementia are still likely to be among the symptoms of a disease that has a long prodromal period. Still 
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we did not find evidence that cognitive performance was more predictive of dementia for shorter versus longer latency 
periods, in contrast to previous findings (3,29,30). 
The strengths of the present study include the large scale of the UK Biobank cohort combined with the rich 
dataset that allowed us to consider multiple validated risk factors for dementia alongside the cognitive data, for 
prediction of all-cause and cause-specific dementia. The age range of the cohort covering mid to late adulthood also 
enabled us to consider cognitive function and dementia risk factors in both earlier and later onset dementias, when 
previous studies have recruited adults at a minimum age of 65 years (3–9,11,12,29–34). A major strength was the use 
of routinely-collected health records to identify dementia cases. Despite the potential issue of under-detecting cases of 
dementia outlined above, this method allowed us to address to a large extent the issue of attrition in previous studies 
that have relied upon active participation at follow-up for ascertainment of dementia, and likely lose representation from 
poor cognitive performers (35).  
Previous longitudinal cohort studies of older adults investigating incident dementia risk according to cognitive 
test performance, report AUC values in the range 0.49 to 0.92 (1). Our own results from UK Biobank therefore fall into 
the high end of this range. For greater comparability however, if we consider our results from ROC curves with age, 
sex, education and cognitive test score entered (AUC: 0.82) with those studies of a similar follow-up period (three to 
eight years) and range of variables, we start to reach similar results: 0.73 to 0.89 (6,7,29,31,32), despite study design 
and selection bias differences. Perhaps what the present study lost in sensitivity from a brief cognitive assessment, it 
gained in sensitivity through completeness of follow-up by means of electronic linkage. Nevertheless, what the data 
from the present study show is that even a brief cognitive test battery has predictive power at the population level. 
Whereas it was not the aim of the present study to find evidence for clinical utility of such a tool, such tests do have the 
advantage of providing greater variation in cognitive ability scores within non-clinical population samples, than say 
memory clinic assessments designed to detect impairment within individuals (i.e. Mini-Mental State Examination). A 
brief cognitive testing tool, developed to encompass the array of cognitive domains typically affected in preclinical 
stages of dementia, and to be age-specific (8), could, for example, be a relatively simple, cost-effective way of recruiting 
an enriched cohort into dementia intervention studies (i.e. clinical trials). Whereas the UK Biobank battery included 
some such domains (e.g. processing speed/reaction time, visual episodic memory), it did not include others (i.e. 
executive function and verbal fluency) (7,8,11,12), unlike the enhanced battery that is being used for follow-up of UK 
Biobank participants returning for brain imaging. In future studies these enhanced cognitive data promise to be valuably 
incorporated into prediction modelling of later incident dementia in this cohort. 
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 One previous study controlled for APOE e4 status, family history of dementia, and modifiable risk factors for 
dementia (including depression, smoking) in its investigation of preclinical cognitive performance and dementia 
prediction (6) – specifically AD. Although the study did not consider whether these established risk factors accounted 
for any of the associations between cognitive performance and dementia risk, the authors reported on models in which 
scores on verbal fluency and verbal memory retained statistical significance in the presence of genetic and modifiable 
risk factor effects. In their most predictive of models the AUC was 0.85 (0.80 to 0.89), which compares to our own of 
0.86 (0.81 to 0.90). We might have expected the effect of cognitive performance on dementia risk to reduce in 
multiple regression models that included genetic and modifiable (vascular) risk factors. Whereas we observed that AD 
risk was defined by a relatively stronger association with APOE e4, and VaD risk was defined more by slower 
processing speed and greater vascular risk factors, it was not evident that these genetic and modifiable influences 
accounted for the observed cognitive deficits. Hence, our data confirm that cognitive profiling adds power to 
prediction models of dementia, though the incremental effects are relatively limited compared with other risk factors 
such as age, at least within the age range of the UK Biobank sample.  
A final point on the role of modifiable risk factors, with respect to the combined and subtype dementia 
analyses presented in Table 3, is that we acknowledge some implications of the differences in apparent aetiologic 
pathways between AD and VaD.  None of the modifiable risk factors (with the exception of depression, which one 
might argue is not modifiable) increased the risk of AD, whereas several increased the risk of VaD.  Genetic factors, 
along with increasing age, were the only other significant predictors of incident AD.  Because of recent failures of 
anti-amyloid therapies, attention is turning to prevention of cognitive impairment via modifiable risk factor 
interventions.  We note, in the present analysis, the fact that modifiable risk factors had almost no impact on the 
performance of the prediction models that included cognitive and genetic factors.  When AD and VaD were combined 
into a single diagnosis their very different risk factor profiles tended to become obscured, and the risk associated with 
vascular risk factors and education seemed to acquire more salience. This was evident despite the fact that AD risk 
factors might have dominated the effect estimates due to the relatively higher population prevalence of AD (i.e. two-
thirds). On the basis of these findings one should not lose sight of the fact that interventions to reduce dementia risk in 
the population may need to be very different for the dementia subtypes. Therefore future studies of this kind should 
attempt to more accurately characterise the subtypes, while not forgetting their greater concurrence in increasing older 
age. 
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 The present study validates the use of the UK Biobank baseline cognitive data for use in dementia-related 
research of this cohort, and highlights that brief, electronically-delivered cognitive tests can add unique value to 
dementia prediction models, with potential benefits to clinical trial selection, and, to population health monitoring.  
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Table 1 
Cognitive tasks during the brief test battery administered at UK Biobank baseline assessment centres 
Cognitive test Description Scoring n 
Reaction time A ‘snap’-like card game in which participants 
were required to press a button as quickly as 
possible if the two cards appearing on the screen 
were identical.  
Mean time 
(milliseconds) to 
correctly identify four 
matched pairs as part 
of 10 trials 
496 787 
Visual memory The test required participants to identify six pairs 
of playing cards each with a different solid-black 
object or symbol. Individual cards were randomly 
assigned to positions on a 3x4 matrix and 
presented to the participant for five seconds, 
before being electronically ‘flipped’.  
Number of errors 
made in identifying 
correct pairs 
497 986 
Verbal-numerical reasoning Referred to by UK Biobank as the ‘fluid 
intelligence test’, this was presented by 13 
multiple-choice items (six verbal, seven 
numerical). 
Scored from 0 to 13 
(scores were 
reversed to indicate 
number of errors) 
165 486 
Prospective memory Participants were informed that, at the end of the 
test battery, they would see four shapes of 
different colours on the screen and would be 
asked to touch a blue square, but instead they 
should touch an orange circle. 
‘1’ for correct first 
time; ‘0’ for incorrect 
first time 
171 579 
Note. The prospective memory and verbal-reasoning tasks were completed by approximately one third of the sample due to their 
later introduction to the UK Biobank baseline assessment. 
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Table 2 
Constitutional and modifiable risk factors measured at UK Biobank baseline and used as covariates in the present study 
Measure Description Reference 
group 
Constitutional   
Educational attainment Touchscreen: indicated by no education beyond secondary school (‘1’), or 
having a college/university degree or equivalent (‘0’), and considered in the 
present study to be a non-modifiable marker of premorbid intellectual 
ability 
college degree 
Family history of dementia Touchscreen: self-reported father/mother/sibling with dementia diagnosis no family 
history 
Neuroticism Touchscreen: scores from 12-item Eysenck Personality Questionnaire (EPQ-
R)-Short Form.  This relatively stable personality trait,  viewed as a non-
modifiable risk factor in the present study, was included due to its 
association with several vascular risk factors (36–38), independent of 
cognitive ability (39). 
lowest quartile 
APOE e4  Genotyped blood data: APOE e4 carrier status (‘1’ for e4 carrier and ‘0’ for 
e4 non-carrier), excluding e2-e4 haplotypes 
non APOE e4 
carrier 
AD polygenic risk Genotyped blood data: AD polygenic risk score was calculated using the 
software PRSice (40) according to individuals’ genotyped blood data and the 
summary statistics from International Genomics of Alzheimer’s Project (41). 
The score was calculated according to effect size estimates of multiple 
single nucleotide polymorphisms (SNPs) found to be significant (p<0.01) in 
case-control studies, with the exclusion of APOE-relevant SNPs given that 
we separately accounted for APOE genotype (see Supplementary Methods 
A for description of genotyping and quality control methods, and, 
accompanying Table S2). 
lowest quartile 
Modifiable risk factors   
Depression Touchscreen: 
I. Baseline risk: a combined score of >3 on the first two items of the 
Patient Health Questionnaire (PHQ-2) that assess the two core 
criteria of depression experienced in the previous two weeks (42) 
II. History: if participant ever visited a GP for depression or anxiety 
 
non-depressed 
 
 
non-depressed 
Midlife hypertension Touchscreen: self-reported regular use of blood pressure (neither self-
reported hypertension nor physical measures were related to dementia). 
no hypertension 
Hyperlipidaemia Touchscreen and nurse interview: self-reported regular use of cholesterol 
lowering medication, or, at nurse interview reported high cholesterol or 
named a cholesterol-lowering medication being taken (Table S3 lists these 
medications). 
no high 
cholesterol 
Diabetes Touchscreen and nurse interview: self-reported regular use of insulin, or at 
nurse interview, reported diagnosis or taking of a diabetes-related 
medication (see Table S4 for list of medications); consistent with a 
previously published algorithm (43) 
no diabetes 
Obesity Anthropometric measures (44):  
I. Total obesity: body mass index (BMI) of ≥30 
II. Central obesity: waist-to-hip ratio (WHR) ≥0.85 women; ≥0.90 men 
 
no obesity 
no obesity 
Low physical activity level Touchscreen: categorised as low (0), moderate (1), or high (2), according to 
World Health Organisation recommendations (45): low = activity less than 
moderate; moderate activity = 2.5 hr/week moderate or 75 minutes/week 
vigorous, or, >once per week, or equivalent; high activity (for additional 
health benefits) = 300 minutes/week moderate or 150 minutes/week 
vigorous, or equivalent. Four self-report items from the International 
Physical Activity Questionnaire–Short Form covering the frequency and 
duration of moderate or vigorous physical activity during an average week.  
high activity 
Smoker Touchscreen: self-reported never (0), ex-smoker (1), or current smoker (2) never smoked 
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Table 3 
Odds ratios (and 95% confidence intervals) for a first diagnosis of dementia made at least 3 years after baseline, according to established risk factors 
 
 All-cause dementia 
N = 385 336 (591 cases) § 
 Alzheimer’s disease 
N = 384 937 (192 cases) 
 Vascular dementia 
N = 384 837 (92 cases) 
  No dementia at 
follow-up 
% 
Dementia at 
follow-up 
% 
 
OR (95% CI) 
 No AD at 
follow-up 
% 
AD at  
follow-up 
% 
 
OR (95% CI) 
 No VaD at 
follow-up 
%  
VaD at  
follow-up 
% 
 
OR (95% CI) 
Male  45.1 55.5 1.39 (1.18, 1.63)*  45.1 48.4 1.04 (0.78, 1.38)  45.1 62.0 1.81 (1.19, 2.75) 
Age at baseline  56.3 yrs 64.2 yrs 1.21 (1.19, 1.23)*  56.3 yrs 64.4 yrs 1.22 (1.18, 1.26)*  56.3 yrs 64.4 yrs 1.22 (1.16, 1.28)* 
Education, no degree  65.1 78.7 1.48 (1.22, 1.81)*  65.1 77.6 1.35 (0.96, 1.90)  65.1 83.7 2.09 (1.20, 3.64) 
             
Constitutional             
APOE e4 carrier  30.8 56.7 2.99 (2.43, 3.68)*  30.8 65.1 4.28 (2.97, 6.18)*  30.8 49.2 2.22 (1.33, 3.70) 
AD PGSnoAPOE, Q4†  25.0 30.8 1.41 (1.06, 1.88)  25.0 38.1 2.11 (1.28, 3.47)  25.0 28.8 2.49 (1.03, 6.01) 
Family history of dementia  12.3 23.2 1.65 (1.36, 2.00)*  12.3 29.7 2.29 (1.68, 3.12)*  12.3 28.3 2.16 (1.37, 3.41)* 
Neuroticism, Q4†  24.6 24.5 1.45 (1.15, 1.84)*  24.6 22.9 1.13 (0.75, 1.69)  24.6 29.4 1.76 (1.01, 3.07) 
             
Modifiable              
Depression              
   PHQ-2  5.5 8.1 2.25 (1.67, 3.03)*  5.5 8.3 2.31 (1.38, 3.86)*  5.5 10.9 3.19 (1.65, 6.17)* 
   GP visit  33.8 38.2 1.47 (1.24, 1.74)*  33.8 37.0 1.34 (0.99, 1.80)  33.8 40.2 1.68 (1.10, 2.57) 
Hypertension  19.8 38.9 1.39 (1.17, 1.64)*  19.8 32.3 1.04 (0.76, 1.41)  19.8 50.0 2.12 (1.40, 3.22)* 
Hypercholesterolemia   16.9 35.7 1.36 (1.14, 1.61)*  16.9 28.1 0.97 (0.70, 1.34)  16.9 50.0 2.38 (1.56, 3.64)* 
Diabetes  4.6 11.5 1.75 (1.36, 2.26)*  4.6 8.9 1.35 (0.82, 2.24)  4.6 18.5 2.93 (1.72, 4.99)* 
Obesity‡              
   Overall  24.0 24.5 1.01 (0.84, 1.22)  24.0 22.4 0.90 (0.64, 1.26)  24.0 33.7 1.57 (1.02, 2.42) 
   Central  48.1 61.3 1.16 (0.97, 1.40)  48.1 53.7 0.91 (0.67, 1.25)  48.1 67.4 1.40 (0.87, 2.25) 
Low physical activity  16.8 16.8 1.23 (0.98, 1.54)   16.8 12.5 0.82 (0.52, 1.27)  16.8 18.5 1.62 (0.91, 2.88) 
Current smoker  9.9 11.2 1.53 (1.17, 2.01)*  9.9 8.9 1.13 (0.67, 1.90)  9.9 13.0 1.81 (0.95, 3.47) 
             
Note. All OR (odds ratios) are from models that adjust for age and sex; those including APOE or AD PGS additionally adjust for genetic batch, array, assessment centre, and the first ten principal 
components to explain population structure. *Statistically significant after Bonferroni correction: 0.05/26 tests per outcome in univariate and multivariate regression models = p-value of 0.0019. 
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§All except for APOE e4 and AD PGSnoAPOE (all-cause: n = 224 054, cases = 367; AD: n = 223 813, cases = 126; VaD: n = 223 746, cases = 59). †Q4 = highest quartile group; reference group is 
lowest quartile. ‡Overall obesity: BMI≥30; central obesity: WHR ≥0.85 in women and ≥0.90 in men.  
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Table 4 
Prediction of incident dementia according to UK Biobank baseline cognitive tests, adjusted for age, sex and education 
Cognitive test Total dementia 
 
Alzheimer’s disease 
 
Vascular dementia 
 
n (cases) 385 336 (591) 384 937 (192) 384 837 (92) 
Reaction time (1 SD milliseconds) 1.31 (1.22, 1.41)* 1.24 (1.09, 1.41)* 1.56 (1.32, 1.84)* 
Visual memory (1 SD errors) 1.27 (1.18, 1.36)* 1.24 (1.10, 1.41)* 1.20 (1.00, 1.44) 
n (cases) 130 212 (115) 130 139 (42) 130 118 (21) 
Verbal-numerical (1 SD incorrect)  1.68 (1.36, 2.07)* 1.84 (1.30, 2.61)* 1.56 (0.97, 2.52) 
Prospective memory (incorrect first time) 3.28 (2.26, 4.75)* 4.72 (2.51, 8.88)* 2.86 (1.20, 6.80) 
 
 
Note. Odds ratios (and 95% confidence intervals) for incident dementia risk are association with a one standard deviation (SD) 
higher score on the cognitive measure (i.e. higher reaction time, or higher number of incorrect responses), except for prospective 
memory that is in association with an incorrect first response. *Statistically significant after Bonferroni correction: 0.05/26 tests per 
outcome in univariate and multivariate regression models = p-value of 0.0019.    
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Table 5 
Incident all-cause dementia risk predicted by baseline cognitive tests, adjusted for constitutional and modifiable risk 
factors 
  Model 1 Model 2 Model 3 
N | cases  397 485 | 646   
Reaction time (1 SD milliseconds) 
include cases with APOE e4 status§ 
 1.31 (1.22, 1.40)* 
1.31 (1.20, 1.43)* 
1.30 (1.22, 1.39)* 
1.33 (1.22, 1.45)* 
1.28 (1.20, 1.37)* 
1.31 (1.20, 1.43)* 
Visual memory (1 SD errors) 
include cases with APOE e4 status§ 
 1.22 (1.14, 1.30)* 
1.21 (1.11, 1.32)* 
1.21 (1.13, 1.30)* 
1.19 (1.09, 1.30)* 
1.21 (1.13, 1.30)* 
1.19 (1.09, 1.30)* 
N | cases  134 623 | 122   
Verbal-numerical (1 SD incorrect)  
include cases with APOE e4 status† 
 1.69 (1.38, 2.07)* 
1.87 (1.42, 2.48)* 
1.71 (1.40, 2.10)* 
1.80 (1.10, 2.92) 
1.67 (1.36, 2.04)* 
1.72 (1.06, 2.81) 
Prospective memory (incorrect) 
include cases with APOE e4 status† 
 3.23 (2.26, 4.64)* 
3.50 (2.15, 5.67)* 
3.29 (2.29, 4.71)* 
3.12 (1.35, 7.19) 
3.16 (2.20, 4.55)* 
3.00 (1.30, 6.96) 
 
Note. Odds ratios (and 95% confidence intervals) for incident dementia risk are in association with a one standard deviation (SD) 
higher score on the cognitive measure, except for prospective memory that is in association with a correct first response. Model 1 
covariates include age, sex, and education; Model 2 covariates include family history of dementia and neuroticism, and APOE e4 
where stated (as in Tables S8-11) + Model 1 covariates; Model 3 adds modifiable risk factors (as in Tables S8-11) to Model 2, 
including current and past depression, hypertension, hypercholesterolemia, diabetes, and, smoking. *Statistically significant after 
Bonferroni correction: 0.05/26 tests per outcome in univariate and multivariate regression models = p-value of 0.0019). §Models 
include n = 230 539 (393 dementia cases). †Models include n = 76 326 (68 dementia cases).
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 Figure 1   
ROC curves for the prediction of incident dementia according to: (1) age, sex and education, (2) + family history with 
APOE e4 (left-hand graph) or without (right-hand graph) APOE e4; (3) + self-reported depression rating; (4) + cognitive 
test performance. Sample sizes are: (left-hand graph) 81 823 including 78 dementia cases; (right-hand graph) 145 068 
participants including 141 dementia cases. 
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Supplementary Methods A: Genotyping for AD risk and quality control. 
 
The majority of UK Biobank participants have genomic data (97.2%; N=488 377), including 49 950 genotyped using 
the UK BiLEVE array and 438 427 using the UK Biobank axiom array - with 95% content in common between the two 
(1), covering 805 426 markers. Quality control procedures in the present study match those of previous studies by co-
authors (2,3), involving exclusion of participants on the grounds of missingness, relatedness, gender mismatch, and non-
British ancestry (to reduce population stratification), and resulted in available data for 331,689 individuals. 
The genotyped array data were firstly used for the characterisation of apolipoprotein E (APOE) haplotypes, 
extracted from the following basepairs on chromosome 19: 44909039 to 45912650; variants rs429358 and rs7412. 
Individuals carrying haplotype e2e4 were removed from the analyses, given competing risks of e2 and e4 alleles. Data 
on APOE e4 carrier and non-carrier status were available for 282 311 individuals.  
Secondly, polygenic scores for AD risk were estimated according to summary GWAS scores provided by the 
International Genomics and Alzheimer’s Project (4) using the software PRSice (5). Each score was calculated according 
to the effect size estimates of multiple single nucleotide polymorphisms (SNPs) found to be significant in AD case-
control studies, according to thresholds of P<1.0, P<0.5, P<0.1, P<0.05, and, P<0.01 respectively. PRSice calculates the 
sum of alleles associated with AD across many genetic loci, weighted by their effect sizes estimated from a GWAS of 
the corresponding phenotype in an independent sample. Therefore in the present study GWAS summary statistics for 
AD from published GWAS case-control studies and provided by the international consortium were used as the training 
(base) dataset, and UK Biobank was used as the prediction (target) dataset. We removed SNPs with a minor allele 
frequency below 0.01, and non-autosomal variants, before creating the polygenic scores. SNPs in linkage disequilibrium 
were obtained by clumping with an r2 < 0.25 within a 250kb window. Given that we were separately accounting for 
APOE genotype in the present study’s main analysis, polygenic scores were calculated without APOE-relevant SNPs 
(i.e. those within a 500kb window of the APOE gene) – ‘AD PGSnoAPOE’. We selected the AD polygenic score estimated 
from the most conservative number of SNPs (P<0.01) given that its effect on incident dementia (especially AD) risk 
was greater than that of other thresholds (see S4 Table). 
References 
1. Bycroft C, Freeman C, Petkova D, Band G, Elliott LT, Sharp K, et al. Genome-wide genetic data on ~500,000 UK 
Biobank participants. bioRxiv [Internet]. 2017 [cited 2017 Aug 8]; Available from: 
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2. Hagenaars SP, Radaković R, Crockford C, Fawns-Ritchie C, Harris SE, Gale CR, et al. Genetic risk for 
neurodegenerative disorders, and its overlap with cognitive ability and physical function. PLoS One. 
2018;13(6):e0198187.  
3. Luciano M, Hagenaars SP, Davies G, Hill WD, Clarke T-K, Shirali M, et al. 116 independent genetic variants 
influence the neuroticism personality trait in over 329,000 UK Biobank individuals. bioRxiv [Internet]. 2017 
[cited 2017 Aug 8]; Available from: http://www.biorxiv.org/content/early/2017/07/28/168906 
4. Lambert JC, Ibrahim-Verbaas CA, Harold D, Naj AC, Sims R, Bellenguez C, et al. Meta-analysis of 74,046 
individuals identifies 11 new susceptibility loci for Alzheimer’s disease. Nat Genet. 2013;45(12):1452–8.  
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5 
 
Supplementary Methods B: Details and handling of missing data. 
 
The main analyses selected participants with complete data only on the exposure variables (reported in Tables 2 to 5 of 
the main article). Notable missing data where participants had the opportunity to provide complete data but didn’t (>5%) 
were observed for neuroticism (8.2%) ─ reliant upon full or near completion of multiple self-report items, self-rated 
depression (7.0%) and family history of dementia (5.1%) (see Table S6 for numbers of participants with data on each 
variable). Stringent quality control and exclusion criteria of genetic data led to 44% and 34% missing data for APOE e4 
status and AD polygenic scores respectively. Of the cognitive measures, approximately a third of the cohort had data on 
verbal-numerical reasoning and prospective memory due to the later introduction of these tasks to the baseline cognitive 
test battery (see Table 1 of the main manuscript). In general, the analytic sample differed from the rest of the entire UK 
Biobank sample in that it was better educated, lower on neuroticism, scored higher on the cognitive tests, and had fewer 
modifiable risk factors for dementia (see Table S5).  To attempt to address this bias and reduce the fall-out from missing 
data, we repeated multiple regression models and included participants with missing data in a separate category for each 
entered variable with substantive missingness (i.e. neuroticism, self-rated depression, and, family history of dementia), 
except for APOE e4 status and the two cognitive tasks for which the majority of missing data were unrelated to 
participant choice. Table S13 reports these results.   
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Figure S1. Time in years to dementia diagnoses. 
 
Figure S1a 
Time in years to dementia diagnoses (N = 1051) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S1b 
Time in years to dementia diagnoses: Main analytic sample (N = 591) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
M = 5.23 (SD = 1.24) 
M = 5.24 (SD = 1.23) 
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Figure S1c 
Time in years to dementia diagnoses: Genetic sample (N = 367) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S1d 
Time in years to dementia diagnoses: Full cognitive battery Sample (N = 115) 
 
 
 
 
 
 
 
  
M = 5.23 (SD = 1.30) 
M = 4.33 (SD = 0.83) 
M = 5.30 (SD = 1.23) 
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S1 Table. Identifying dementia cases from hospital and death data (n = 1472). 
 
Description 
 
ICD10 
codes 
ICD9 codes Hospital 
admissions 
N 
Deaths 
N 
Dementia in Alzheimer Disease 
 
early onset 
late onset 
atypical or mixed type 
unspecified 
 
F00 
F000 
F001 
F002 
F009 
 
331.0 
34 - 
Vascular dementia* 
 
acute onset 
multi-infarct 
subcortical 
mixed cortical and subcortical 
other 
unspecified 
 
F01 
F01.0 
F01.1 
F01.2 
F01.3 
F01.8 
F01.9 
 
290.4, 290.40, 290.41, 290.42, 290.43 
195 46 
 
 
 
Dementia in: 
 
Pick disease 
Creutzfeldt-Jakob disease 
Huntington’s disease 
Parkinson disease 
HIV 
Other specified diseases 
 
F02 
F02.0 
F02.1 
F02.2 
F02.3 
F02.4 
F02.8 
 
 
331.11 
046.11 
333.4 
 
 
294.1, 294.10, 294.11 
48 
 
- 
Unspecified dementia  
F03 
 
290, 290.0, 290.1, 290.10, 290.11, 290.12, 
290.13, 290.2, 290.20, 290.21, 290.3, 290.9, 
292.82, 294.2, 294.20, 294.21 
461 124 
Delirium superimposed on dementia  
F05.1 
 
293.0, 293.1, 293.9 
22 - 
Mental and behavioural disorders due to use 
of alcohol - amnesic syndrome 
 
F10.6 
 
291.1, 291.2 
34 7 
Alzheimer Disease† 
 
early onset 
late onset 
other 
unspecified 
 
G30 
G30.0 
G30.1 
G30.8 
G30.9 
 369 76 
 
Other dementias 
- frontotemporal dementia 
- senile degeneration of the brain 
- Other degenerative diseases of nervous 
system 
- dementia with lewy bodies 
 
G31.0 
G31.1 
G31.8 
 
G31.83 
 
331.1, 331.19 
331.2 
331.8 
 
331.82 
195 
 
60 
Binswanger’s disease  
I67.3 
 7 - 
Sporadic Creutzfeld-Jakob disease  
A81.0 
 17 18 
 Total  1382 331 
N incident cases   1472 
 
Notes. All of the listed codes were used to identify all-cause dementia cases. *Indicates codes used to identify vascular 
dementia (VaD); †Indicates codes used to identify AD. 
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S2 Table. Associations between AD polygenic risk score (without APOE) and 
incident dementia according to five different SNP thresholds. Models are 
adjusted for age, sex, genetic batch, genetic array, assessment centre, and 10 
principal components of population structure. 
 
  All-cause dementia AD VaD 
AD PGS Threshold SNPs, n OR 95% CI OR 95% CI OR 95% CI 
        
0.01 3199 1.12 1.04, 1.21 1.21 1.07, 1.36 1.13 0.93, 1.37 
0.05 13 025 1.11 1.03, 1.19 1.14 1.01, 1.29 1.22 1.00, 1.49 
0.1 23 794 1.09 1.02, 1.18 1.08 0.96, 1.23 1.17 0.96, 1.43 
0.5 93 575 1.09  1.01, 1.17 1.04 0.92, 1.18 1.20 0.99, 1.47 
1 151 005 1.10 1.02, 1.18 1.03 0.91, 1.17 1.21 0.99, 1.47 
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S3 Table. List of cholesterol lowering medications reported at nurse interview 
and used to identify hyperlipidaemia. 
 
UK Biobank medication code British National Formulary drug or brand name 
1141146234 atorvastatin 
1141146138 lipitor 10mg tablet 
1140888594 fluvastatin 
1140864592 lescol 20mg capsule 
1140888648 pravastatin 
1140861970 lipostat 10mg tablet 
1141192410 rosuvastatin 
1141192414 crestor 10mg tablet 
1140861958 simvastatin 
1140881748 zocor 10mg tablet 
1141188146 simvador 10mg tablet 
1141192736 ezetimibe 
1141192740 ezetrol 10mg tablet 
1140861924 bezafibrate 
1141201306 fibrazate xl 400mg m/r tablet 
1140861926 bezalip 200mg tablet 
1140861928 bezalip-mono 400mg m/r tablet 
1140862026 ciprofibrate 
1140861954 fenofibrate 
1141162544 lipantil micro 67mg capsule 
1141172214 supralip 160mg m/r tablet 
1140861856 gemfibrozil 
1141157262 gemfibrozil product 
1140861858 lopid 300 capsule 
1140861892 acipimox 
1140861894 olbetam 250mg capsule 
1140861868 nicotinic acid product 
1141188546 niaspan 500mg m/r tablet 
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S4 Table. List of medications for diabetes reported at nurse interview. 
 
UK Biobank medication code British National Formulary drug or brand name 
1140883066 Insulin 
 
 Metformin 
1140884600 metformin 
1140874686 gestronol 
1141189090 rosiglitazone 1mg / metformin 500mg tablet 
 
 Sulfonylureas 
1140874718  
1140874744 
1140874746 
1141152590  
1141156984 
1140874646 
1141157284  
1140874652 
1140874674 
1140874728 
glibenclamide 
gliclazide 
diamicron 80mg tablet 
glimepiride 
amaryl 1mg tablet 
glipizide 
glipizide product 
minodiab 2.5mg tablet 
tolbutamide 
euglucon 2.5mg tablet 
 
 Other oral anti-diabetic medications 
1140868902  
1140868908 
1140857508 
acarbose 
glucobay 50mg tablet 
glucotard 5g/sachet mini-tablet 
 
 Meglitinides 
1141173882  
1141173786 
1141168660 
nateglinide 
starlix 60mg tablet 
repaglinide 
 
 Glitazones 
1141171646  
1141171652 
1141153254 
1141177600 
1141177606 
pioglitazone 
actos 15mg tablet 
troglitazone 
rosiglitazone 
avandia 4mg tablet 
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S5 Table. Characteristics of participants included in main univariate analyses with 
those among: (i) excluded cases, (ii) the genetic sample, and (iii) the full cognitive 
test sample.  
 Main univariate analyses Subset analyses 
 
Complete  
cases 
Excluded 
sample 
p-value for 
difference 
Genetic  
sample 
Full cognitive 
test sample 
N 385 336* 117 156  224 054 130 212 
Incident dementia 0.15% 0.39% <.001 0.16% 0.09% 
Age at dementia diagnosis 66.2 yrs 69.4 yrs <.001 69.6 yrs 67.9 yrs 
      
Constitutional risk factors      
Sex, male 45.1% 47.1% <.001 45.9% 45.2% 
Age at baseline 56.3 yrs 57.2 yrs <.001 56.5 yrs 56.5 yrs 
Education, no college 65.1% 75.0% <.001 65.6% 63.7% 
APOE e4 30.9% 31.0% .490 30.9% 30.4% 
AD PGSnoAPOE, Q4 25.0% 25.3% .505 25.0% 24.9% 
Family history 12.3% 11.9% <.001 12.9% 16.2% 
Neuroticism, Q4 22.4% 25.5% <.001 24.2% 24.4% 
      
Modifiable risk factors      
Depression, PHQ2 5.5% 8.2% <.001 4.9% 5.6% 
Depression, GP 33.8% 34.9% <.001 33.9% 33.5% 
Hypertension 19.9% 25.3% <.001 20.0% 20.2% 
Hypercholesterolemia 17.0% 21.5% <.001 17.6% 17.9% 
Diabetes 4.6% 7.0% <.001 4.3% 4.9% 
Obesity 24.0% 27.5% <.001 23.6% 24.0% 
Central obesity 48.1% 54.3% <.001 48.1% 49.4% 
Low physical activity 16.8% 15.7% <.001 16.7% 15.4% 
Current smoking 9.9% 12.9% <.001 9.4% 9.5% 
      
Cognitive measures      
Reaction time, millisecond 552 571 <.001 549 559 
Verbal memory, errors 3.99 4.08 <.001 3.96 3.92 
Verbal-numerical reasoning score 6.15 5.35 <.001 6.32 6.15 
Prospective memory, correct 79.4 65.8 <.001 82.0 79.8 
Notes. PGS = polygenic score; PSQ2 = Patient Health Questionnaire; GP = general practitioner. *Sample size for all variables 
with the exception of APOE e4 and AD polygenic score (n = 224 054), verbal numerical reasoning (n = 130 212), and prospective 
memory (n = 132 879).  
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S6 Table. Odds ratios (and 95% CI) for incident dementia (>3 years after baseline) according to established risk factors: 
Comparison of differently selected samples. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Note. All OR (odds ratios) are from models that adjust for age and sex; those including APOE or AD PGS, with a smaller sample size, additionally adjust for genetic batch, array, assessment 
centre, and the first ten principal components to explain population structure. *Q4 = highest quartile group; reference group is lowest quartile. §Overall obesity: BMI≥30; central obesity: WHR 
≥0.85 in women and ≥0.90 in men. 
 
 Total sample: 
cases with missing data 
 
Complete cases: 
main univariate analysis 
 
Subset complete cases: 
Full cognitive test sample 
Exposure  N | Cases OR (95% CI)  N | Cases OR (95% CI)  N | Cases OR (95% CI) 
Sex, male   1051 | 502 139 1.40 (1.24, 1.58)  591 | 385 336 1.39 (1.18, 1.63)  115 | 130 212 1.34 (0.93, 1.93) 
Age at baseline, yr  1051 | 502 139 1.20 (1.18, 1.21)  " 1.21 (1.19, 1.23)  " 1.17 (1.13, 1.21) 
Education, non-graduate  986 | 492 014 1.54 (1.32, 1.81)  " 1.48 (1.22, 1.81)  " 1.65 (1.05, 2.57) 
          
Constitutional          
APOE e4 carrier  620 | 282 358  3.14 (2.67, 3.68)  367 | 224 054 2.99 (2.43, 3.68)  63 | 73 985 2.41 (1.47, 3.95) 
AD PGSnoAPOE, Q4*  683 | 331 737 1.36 (1.09, 1.68)  " 1.41 (1.06, 1.88)  " 1.82 (0.90, 3.71) 
Family history of dementia  954 | 476 507 1.82 (1.57, 2.10)  591 | 385 336 1.65 (1.36, 2.00)  115 | 130 212 1.91 (1.29, 2.83) 
Neuroticism, Q4*  924 | 461 101 1.77 (1.45, 2.17)  " 1.45 (1.15, 1.84)  " 1.26 (0.76, 2.09) 
          
Modifiable          
Depression          
   PHQ-2  922 | 467 092 2.69 (2.18, 3.32)  " 2.25 (1.67, 3.03)  " 2.66 (1.42, 4.97) 
   GP visit  1036 | 497 130 1.62 (1.43, 1.84)  " 1.47 (1.24, 1.74)  " 1.40 (0.95, 2.05) 
Hypertension  990 | 493 552 1.44 (1.27, 1.64)  " 1.39 (1.17, 1.64)  " 1.49 (1.01, 2.18) 
Hypercholesterolemia   1051 | 502 139 1.54 (1.36, 1.75)  " 1.36 (1.14, 1.61)  " 1.16 (0.77, 1.74) 
Diabetes  1051 | 502 139 2.15 (1.81, 2.56)  " 1.75 (1.36, 2.26)  " 1.87 (1.06, 3.29) 
Obesity§          
   Overall  995 | 492 035 1.12 (0.97, 1.28)  " 1.01 (0.84, 1.22)  " 1.24 (0.83, 1.86) 
   Central  1040 | 499 882 1.18 (1.03, 1.35)  " 1.16 (0.97, 1.40)  " 1.61 (1.05, 2.46) 
Low physical activity  983 | 489 938 1.55 (1.26, 1.91)  " 1.23 (0.98, 1.54)  " 1.49 (0.90, 2.48) 
Smoking, current (vs never)  1038 | 499 195 1.56 (1.28, 1.89)  " 1.53 (1.17, 2.01)  " 1.00 (0.49, 2.02) 
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S7 Table. Odds ratios (and 95% confidence intervals) for: i) incident dementia at 
least 3 years after baseline; ii) incident dementia and/or all-cause mortality; iii) 
all-cause mortality. 
 
  All dementias 
 
(cases ≤ 1051) 
 All dementias and 
deaths 
(cases ≤ 14,895) 
 Deaths 
 
(cases ≤ 14,421) 
Exposure   
OR (95% CI) 
  
OR (95% CI) 
  
OR (95% CI) 
Sex, male  1.40 (1.24, 1.58)***  1.78 (1.72, 1.84)***  1.81 (1.75, 1.87)*** 
Age at baseline, yr  1.20 (1.18, 1.21)***  1.09 (1.09, 1.10)***  1.09 (1.09, 1.09)*** 
Education, non-graduate  1.54 (1.32, 1.81)***  0.71 (0.69, 0.74)***  0.72 (0.69, 0.75)*** 
       
Constitutional       
APOE e4 carrier  3.14 (2.67, 3.68)***  1.08 (1.03, 1.13)***  1.02 (0.97, 1.07) 
Family history of dementia  1.82 (1.57, 2.10)***  0.89 (0.85, 0.94)***  0.86 (0.82, 0.91)*** 
AD PGSnoAPOE, Q4 vs Q1  1.36 (1.09, 1.68)**  1.00 (0.94, 1.06)  0.99 (0.94, 1.05) 
Neuroticism, Q4 vs Q1  1.77 (1.45, 2.17)***  1.26 (1.19, 1.33)***  1.24 (1.18, 1.31)*** 
       
Modifiable        
Depression        
   PHQ-2  2.69 (2.18, 3.32)***  1.88 (1.77, 2.01)***  1.85 (1.74, 1.97)*** 
   GP visit  1.62 (1.43, 1.84)***  1.25 (1.21, 1.30)***  1.24 (1.19, 1.28)*** 
Hypertension  1.44 (1.27, 1.64)***  1.52 (1.46, 1.57)***  1.51 (1.45, 1.56)*** 
Hypercholesterolemia   1.54 (1.36, 1.75)***  1.49 (1.44, 1.54)***  1.48 (1.42, 1.53)*** 
Diabetes  2.15 (1.81, 2.56)***  2.17 (2.06, 2.28)***  2.15 (2.04, 2.26)*** 
Obesity        
   Overall  1.12 (0.97, 1.28)  1.31 (1.27, 1.36)***  1.32 (1.27, 1.37)*** 
   Central  1.18 (1.03, 1.35)*  1.37 (1.32, 1.43)***  1.38 (1.32, 1.43)*** 
Low physical activity  1.55 (1.26, 1.91)***   1.67 (1.58, 1.76)***  1.69 (1.60, 1.78)*** 
Smoking, current (vs never)  1.56 (1.28, 1.89)***  2.98 (2.85, 3.13)***  3.06 (2.92, 3.21)*** 
       
Cognitive       
Verbal-numerical reasoning  0.53 (0.45, 0.62)***  0.88 (0.85, 0.91)***  0.89 (0.86, 0.92)*** 
Reaction time  1.35 (1.28, 1.43)***  1.14 (1.12, 1.16)***  1.14 (1.12, 1.16)*** 
Visual memory  1.17 (1.10, 1.23)***  1.03 (1.01, 1.04)**  1.02 (1.00, 1.03) 
Prospective memory  0.40 (0.31, 0.52)*** 
 
 0.76 (0.72, 0.83)***  0.79 (0.74, 0.85)*** 
 
Notes. Given common risk factors between dementia and mortality, and, given that logistic regression does not take account of survival and 
therefore may be subject to bias, we repeated the univariate models from the main Results section with death as the outcome, with and without 
dementia. We summarise that whereas smoking, obesity and male sex were stronger risk factors for mortality than they were for dementia – thus 
perhaps reducing their effect sizes for incident dementia – all other risk factors, except for family history of dementia, were in the same direction 
but held weaker associations with mortality (or null, as in the case of the genetic risk factors), and were therefore unlikely to have substantively 
biased the results.  
 
PGS = polygenic score; PSQ2 = Patient Health Questionnaire; GP = general practitioner. All univariate models adjust for age and sex; those 
including APOE or AD PGS additionally adjust for genetic batch, array, assessment centre, and the first ten principal components to explain 
population structure; cognitive models additionally adjust for education. Asterisks: *p<.05; **p<.01; ***p<.001. 
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Table S8. Prediction of incident dementia according to UK Biobank baseline cognitive tests, adjusted for age, sex and 
education: Comparison of differently selected samples. 
 
  
Total sample: 
incl. cases with missing data 
 Complete cases 
   Main univariate analytic sample  Full cognitive test sample 
  
N (cases) OR (95% CI)  N (cases) OR (95% CI) 
 
N (cases) OR (95% CI) 
Reaction time (n milliseconds)  484 599 (917) 1.35 (1.28, 1.43)  385 336 (591) 1.31 (1.22, 1.41)  130 212 (115) 1.50 (1.29, 1.73) 
Visual memory (n incorrect)  488 130 (961) 1.17 (1.10, 1.23)  385 336 (591) 1.27 (1.18, 1.36)  130 212 (115) 1.44 (1.23, 1.67) 
Verbal-numerical reasoning (n incorrect)   163 868 (192) 1.89 (1.61, 2.22)     130 212 (115) 1.68 (1.36, 2.07) 
Prospective memory (incorrect)  169 457 (228) 2.49 (1.92, 3.24)     130 212 (115) 3.28 (2.26, 4.75) 
          
     Main univariate analytic sample 
     3-5 years from cognitive testing to 
dementia diagnosis 
  6-8 years from cognitive testing to 
dementia diagnosis 
Reaction time (n milliseconds)  - -  385 161 (416) 1.31 (1.20, 1.42)  384 920 (175) 1.32 (1.16, 1.50) 
Visual memory (n incorrect)  - -  385 161 (416) 1.23 (1.13, 1.34)  384 920 (175) 1.35 (1.19, 1.52) 
          
 
Note. Odds ratios (and 95% confidence intervals) for incident dementia risk are association with a one SD higher score on the cognitive measure (i.e. higher reaction time, or higher number of 
incorrect responses), except for prospective memory that is in association with an incorrect first response.  
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S9 Table. Prediction of incident dementia by reaction time, and constitutional and modifiable risk factors. 
 
 Total dementia (n = 230 539) Alzheimer’s disease (n = 248 083) Vascular dementia (n = 427 154) 
 
Model 1 Model 2 Model 3 Model 1 Model 2 Model 3 Model 1 Model 2 Model 3 
Cases, n 393 393 393 158 158 158 108 108 108 
Exposure          
Sex, male 1.38 (1.13, 1.68) 1.43 (1.17, 1.23) 1.36 (1.11, 1.68) 1.06 (0.78, 1.46) 1.09 (0.80, 1.49) 1.10 (0.80, 1.51) 1.97 (1.34, 2.91) 2.00 (1.35, 2.95) 1.72 (1.16, 2.55) 
Age at baseline 1.20 (1.17, 1.23) 1.20 (1.18, 1.23) 1.20 (1.17, 1.23) 1.20 (1.16, 1.24) 1.20 (1.16, 1.24) 1.20 (1.16, 1.25) 1.20 (1.15, 1.25) 1.20 (1.14, 1.25) 1.18 (1.13, 1.24) 
Education, non-grad 1.53 (1.19, 1.96) 1.52 (1.18, 1.96) 1.45 (1.13, 1.87) 1.32 (0.90, 1.94) 1.37 (0.93, 2.01) 1.34 (0.91, 1.97) 1.82 (1.09, 3.02) 1.85 (1.11, 3.07) 1.68 (1.01, 2.80) 
Reaction time 1.31 (1.20, 1.43) 1.33 (1.22, 1.46) 1.31 (1.20, 1.43) 1.29 (1.12, 1.49) 1.31 (1.14, 1.51) 1.30 (1.13, 1.50) 1.58 (1.36, 1.84) 1.58 (1.36, 1.84) 1.53 (1.32, 1.78) 
APOE e4  2.91 (2.38, 3.56) 2.91 (2.38, 3.56)  4.25 (3.05, 5.93) 4.26 (3.05, 5.95)  - - 
Family history  1.54 (1.21, 1.95) 1.55 (1.22, 1.97)  2.11 (1.49, 2.97) 2.09 (1.48, 2.95)  2.15 (1.41, 3.28) 2.22 (1.46, 3.39) 
Neuroticism  1.16 (1.00, 1.34) 1.01 (0.87, 1.19)  - -  - - 
Depression, PHQ2   1.93 (1.31, 2.84)   2.74 (1.60, 4.69)   2.47 (1.34, 4.54) 
Depression, GP   1.30 (1.04, 1.63)   -   - 
Hypertension   1.32 (1.04, 1.63)   -   1.34 (0.87, 2.07) 
Hypercholesterolemia   1.03 (0.81, 1.32)   -   1.70 (1.07, 2.69) 
Diabetes   1.48 (1.06, 2.09)   -   1.70 (1.00, 2.90) 
Current smoking   1.26 (0.89, 1.78)   -   - 
 
Notes. PSQ2 = Patient Health Questionnaire; GP = general practitioner. Those exposure variables that were significant predictors in univariate logistic regression models only are included in 
the multiple regression models. Models including APOE additionally adjust for genetic batch, array, assessment centre, and the first ten principal components to explain population structure. 
Odds ratios in bold font are statistically significant (p<.001). 
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 S10 Table. Prediction of incident dementia by visual memory, and constitutional and modifiable risk factors. 
 
 Total dementia (n = 230 539) Alzheimer’s disease (n = 248 083) Vascular dementia (n = 427 154) 
 
Model 1 Model 2 Model 1 Model 1 Model 1 Model 3 Model 1 Model 2 Model 3 
Cases, n 393 393 108 108 108 158 108 108 108 
Exposure          
Sex, male 1.30 (1.07, 1.59) 1.37 (1.12, 1.67) 1.30 (1.06, 1.61) 1.01 (0.74, 1.25) 1.04 (0.76, 1.43) 1.06 (0.77, 1.45) 1.80 (1.22, 2.65) 1.82 (1.24, 2.69) 1.57 (1.06, 2.33) 
Age at baseline 1.21 (1.18, 1.24) 1.21 (1.19, 1.22) 1.21 (1.18, 1.24) 1.20 (1.16, 1.25) 1.21 (1.16, 1.25) 1.21 (1.17, 1.25) 1.22 (1.16, 1.27) 1.21 (1.16, 1.27) 1.20 (1.14, 1.25) 
Education, non-grad. 1.56 (1.22, 2.01) 1.56 (1.22, 2.01) 1.49 (1.15, 1.92)  1.34 (0.92, 1.97) 1.39 (0.95, 2.04) 1.36 (0.92, 1.99) 1.93 (1.16, 3.20) 1.96 (1.18, 3.26) 1.76 (1.06, 2.93) 
Visual memory 1.21 (1.11, 1.32) 1.19 (1.09, 1.30) 1.19 (1.09, 1.30) 1.28 (1.12, 1.46) 1.26 (1.10, 1.44) 1.26 (1.10, 1.44) 1.23 (1.05, 1.45) 1.24 (1.05, 1.45) 1.23 (1.05, 1.45) 
APOE e4  2.91 (2.37, 3.56) 2.91 (2.38, 3.56)  4.23 (3.03, 5.90) 4.24 (3.04, 5.19)  - - 
Family history  1.55 (1.22, 1.96) 1.56 (1.23, 1.98)  2.11 (1.50, 2.97) 2.10 (1.49, 2.95)  2.16 (1.42, 3.29) 2.24 (1.47, 3.41) 
Neuroticism  1.16 (1.01, 1.35) 1.02 (0.87, 1.19)  - -  - - 
Depression, PHQ2   1.99 (1.36, 2.93)   2.82 (1.65, 4.83)   2.67 (1.46, 4.91) 
Depression, GP   1.30 (1.04, 1.62)   -   - 
Hypertension   1.36 (1.06, 1.69)   -   1.36 (0.88, 2.10) 
Hypercholesterolemia   1.04 (0.81, 1.33)   -   1.72 (1.09, 2.71) 
Diabetes   1.53 (1.09, 2.15)   -   1.81 (1.06, 3.08) 
Current smoking   1.31 (0.93, 1.85)   -   - 
 
Notes. PGS = polygenic score; PSQ2 = Patient Health Questionnaire; GP = general practitioner. Models including APOE additionally adjust for genetic batch, array, assessment centre, and the 
first ten principal components to explain population structure. Odds ratios in bold font are statistically significant (p<.001). 
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S11 Table. Prediction of total incident dementia by verbal-numerical reasoning, 
and constitutional and modifiable risk factors. 
 
 Total dementia (n = 76 326) 
 
Model 1 Model 2 Model 3 
Cases, n 68 68 68 
Exposure    
Sex, male 1.26 (0.78, 2.04) 0.60 (0.25, 1.41) 0.63 (0.26, 1.51) 
Age at baseline 1.17 (1.10, 1.23) 1.13 (1.04, 1.23) 1.12 (1.03, 1.22) 
Education, non-grad. 1.10 (0.59, 2.04) 2.04 (0.58, 7.21) 2.13 (0.60, 7.59) 
Verbal-numerical r 1.87 (1.42, 2.48) 1.80 (1.10, 2.92) 1.72 (1.06, 2.81) 
APOE e4  1.75 (0.76, 4.04) 1.78 (0.76, 4.16) 
Family history  1.57 (0.64, 3.89) 1.59 (0.64, 3.97) 
Neuroticism  0.65 (0.35, 1.19) 0.56 (0.29, 1.10) 
Depression, PHQ2   5.14 (1.30, 20.3) 
Depression, GP   0.96 (0.36, 2.55) 
Hypertension   2.49 (0.96, 6.44) 
Hypercholesterolemia   0.98 (0.35, 2.72) 
Diabetes   0.47 (0.06, 3.75) 
Current smoking   0.32 (0.04, 2.45) 
 
Notes. GP = general practitioner; PHQ = Patient Health Questionnaire; r = reasoning. Models including APOE additionally adjust 
for genetic batch, array, assessment centre, and the first ten principal components to explain population structure. Odds ratios in 
bold font are statistically significant (p<.001). 
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S12 Table. Prediction of total incident dementia by prospective memory, and 
constitutional and modifiable risk factors. 
 
 Total dementia (n = 76 326) 
 
Model 1 Model 2 Model 3 
Cases, n 68 68 68 
Exposure    
Sex, male 1.25 (0.77, 2.01) 0.59 (0.25, 1.39) 0.63 (0.26, 1.51) 
Age at baseline 1.16 (1.10, 1.22) 1.13 (1.04, 1.22) 1.12 (1.03, 1.22) 
Education, college 1.41 (0.78, 2.56) 2.60 (0.76, 8.91) 2.62 (0.76, 9.06) 
Prospective memory  3.50 (2.15, 5.67) 3.12 (1.35, 7.19) 3.00 (1.30, 6.96) 
APOE e4  1.74 (0.75, 4.03) 1.77 (0.76, 4.13) 
Family history  1.60 (0.65, 3.95) 1.64 (0.66, 4.08) 
Neuroticism  0.66 (0.36, 1.22) 0.58 (0.29, 1.13) 
Depression, PHQ2   5.35 (1.36, 21.0) 
Depression, GP   0.97 (0.36, 2.60) 
Hypertension   2.51 (0.98, 6.43) 
Hypercholesterolemia   0.96 (0.35, 2.68) 
Diabetes   0.48 (0.06, 3.80) 
Current smoking   0.31 (0.04, 2.40) 
 
Notes. PSQ2 = Patient Health Questionnaire; GP = general practitioner. Models including APOE additionally adjust for genetic 
batch, array, assessment centre, and the first ten principal components to explain population structure. Odds ratios in bold font are 
statistically significant (p<.001). 
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S13 Table. Incident dementia risk predicted by baseline cognitive tests and 
adjusted for established risk factors: a comparison of models with complete 
cases versus those including >5% missing data on covariates. 
 
Cognitive test N Model 1 
 
Model 2 
 
Model 3 
 
     
Reaction time, milliseconds 
complete cases 
including missing cases 
 
646 / 397 485 
853 / 473 086 
 
 
1.31 (1.22, 1.40)* 
1.34 (1.26, 1.42)* 
 
1.30 (1.22, 1.39)* 
1.33 (1.25, 1.41)* 
 
1.28 (1.20, 1.37)* 
1.31 (1.23, 1.38)* 
Visual memory, errors 
complete cases 
including missing cases 
 
646 / 397 485 
853 / 473 086 
 
 
1.22 (1.14, 1.30)* 
1.21 (1.15, 1.29)* 
 
1.21 (1.13, 1.30)* 
1.21 (1.14, 1.28)*** 
 
1.21 (1.13, 1.30)* 
1.21 (1.14, 1.28)* 
Verbal-numerical r., errors 
complete cases 
including missing cases 
  
122 / 134 623 
165 / 158 570 
 
 
1.69 (1.38, 2.07)* 
1.82 (1.53, 2.16)* 
 
1.71 (1.40, 2.10)* 
1.81 (1.52, 2.16)* 
 
1.67 (1.36, 2.04)* 
1.74 (1.46, 2.07)* 
Prospective memory, incorrect 
complete cases 
including missing cases 
 
122 / 134 623 
165 / 158 570 
 
 
3.23 (2.26, 4.64)* 
3.01 (2.21, 4.11)* 
 
3.29 (2.29, 4.71)* 
2.98 (2.18, 4.06)* 
 
3.16 (2.20, 4.55)* 
2.78 (2.03, 3.81)* 
 
Notes. Odds ratios (and 95% confidence intervals) for incident dementia risk are in association with a one SD higher score on the 
cognitive measure, except for prospective memory that is in association with an incorrect first response. Model 1 covariates include 
age, sex, and education; Model 2 covariates include family history of dementia, and, neuroticism + Model 1 covariates; Model 3 
adds modifiable risk factors to Model 2, including current and past depression, hypertension, hypercholesterolemia, diabetes, and, 
smoking. Models of cases with missing data include those participants with notable missing data (>5%) on exposure variables 
(neuroticism, family history of dementia, self-rated depression)─with the exception of APOE e4 that was largely missing due to 
quality control factors─and included within an additional category for each exposure. Asterisks indicate statistically significant 
effect estimates: p<0.001. 
The effect estimates and their confidence intervals for models including complete cases and missing cases respectively are similar 
and overlapping. This is evidence that the main results of multivariable logistic regression models were not biased by cases excluded 
due to missing data on exposures (where participants had the opportunity to provide responses)  
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S14 Table. ROC models and comparison of their discriminative accuracy, with and 
without APOE e4 status.  
 
 ROC curves without APOE (n = 145 068; 141 dementia case) 
 Model 1 Model 2 Model 3 Model 4 
 OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) 
Sex, male 1.42 (1.02, 1.98) 1.44 (1.04, 2.02) 1.46 (1.05, 2.04) 1.58 (1.13, 2.21) 
Age at baseline 1.15 (1.11, 1.19) 1.14 (1.11, 1.18) 1.15 (1.11, 1.19) 1.11 (1.08, 1.15) 
Education, non-graduate 1.83 (1.21, 2.77) 1.87 (1.23, 2.83) 1.83 (1.20, 2.77) 1.31 (0.85, 2.02) 
Family history  2.28 (1.62, 3.23) 2.29 (1.62, 3.23) 2.48 (1.75, 3.51) 
Depression, PHQ2   2.57 (1.47, 4.49) 1.75 (0.99, 3.08) 
Reaction time    1.39 (1.22, 1.59) 
Visual memory    1.29 (1.12, 1.49) 
Verbal-numerical r    1.37 (1.12, 1.67) 
Prospective memory    2.16 (1.51, 3.09) 
     
AUC (95% CI) 0.764 (0.727 to 0.801) 0.775 (0.737 to 0.813) 0.780 (0.744 to 0.817) 0.831 (0.795 to 0.867) 
Χ2  -  2.44 1.25 22.34 
p-value - .118 .263 <.001 
     
 ROC curves with APOE (n = 81 823; 78 dementia case) 
 Model 1 Model 2 Model 3 Model 4 
 OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) 
Sex, male 1.21 (0.77, 1.89) 1.22 (0.78, 1.91) 1.24 (0.79, 1.93) 1.36 (0.87, 2.14) 
Age at baseline 1.17 (1.12, 1.23) 1.17 (1.12, 1.23) 1.18 (1.12, 1.24) 1.13 (1.07, 1.18) 
Education, non-graduate 1.65 (0.95, 2.86) 1.66 (0.95, 2.88) 1.62 (0.93, 2.81) 0.97 (0.54, 1.75) 
Family history  1.69 (1.05, 2.72) 1.67 (1.04, 2.70) 1.78 (1.10, 2.87) 
APOE e4 carrier  2.65 (1.69, 4.16) 2.67 (1.70, 4.19) 2.62 (1.67, 4.12) 
Depression, PHQ2   2.76 (1.26, 6.04) 1.95 (0.88, 4.31) 
Reaction time    1.58 (1.33, 1.89) 
Visual memory    1.32 (1.09, 1.59) 
Verbal-numerical r    1.51 (1.15, 1.98) 
Prospective memory    2.44 (1.51, 3.93) 
     
AUC (95% CI) 0.774 (0.724 to 0.824) 0.794 (0.741 to 0.847) 0.802 (0.752 to 0.852) 0.855 (0.806 to 0.904) 
Χ2  -  2.36 1.75 16.40 
p-value - .124 .186 <.001 
     
 
Notes. Odds ratios (and 95% confidence intervals) for incident dementia risk are in association with a one SD higher score on the 
cognitive measure, except for prospective memory that is in association with an incorrect first response. PSQ2 = Patient Health 
Questionnaire. 
